Research ArticleArticle
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein and Brian M. Feldman
The Journal of Rheumatology August 2020, jrheum.191375; DOI: https://doi.org/10.3899/jrheum.191375
Saunya Dover
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Samantha Stephens
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Jane E. Schneiderman
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Eleanor Pullenayegum
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Greg D. Wells
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Deborah M. Levy
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Jo-Anne Marcuz
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Kristi Whitney
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Andreas Schulze
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Ingrid Tein
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Brian M. Feldman
Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca. Accepted for publication July 13, 2020.
Article Information
jrheum.191375
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 15, 2021.
Article Versions
- Latest version (August 1, 2020 - 04:00).
- You are currently viewing a Latest version of this article (January 15, 2021 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2021 The Journal of Rheumatology
Author Information
- Saunya Dover,
- Samantha Stephens,
- Jane E. Schneiderman,
- Eleanor Pullenayegum,
- Greg D. Wells,
- Deborah M. Levy,
- Jo-Anne Marcuz,
- Kristi Whitney,
- Andreas Schulze,
- Ingrid Tein and
- Brian M. Feldman
- Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report.
S. Dover, MSc, Child Health Evaluative Sciences, The Hospital for Sick Children; S. Stephens, PhD, Neurosciences and Mental Health, The Hospital for Sick Children; J.E. Schneiderman, PhD, RKin, CEP, Clinical Research Services, Research Institute, The Hospital for Sick Children, and Faculty of Kinesiology and Physical Education, University of Toronto; E. Pullenayegum, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management and Evaluation, the Dalla Lana School of Public Health, University of Toronto; G.D. Wells, PhD, Translational Medicine, The Hospital for Sick Children; D.M. Levy, MD, MS, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; J.A. Marcuz, MScPT, K. Whitney, MSc, BScPT, Division of Rheumatology, The Hospital for Sick Children, and Department of Rehabilitation, The Hospital for Sick Children; A. Schulze, MD, PhD, Clinical and Metabolic Genetics, The Hospital for Sick Children; I. Tein, MD, FRCPC, Division of Neurology, Department of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto; B.M. Feldman, MD, MSc, FRCPC, Child Health Evaluative Sciences, The Hospital for Sick Children, and Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, and Department of Pediatrics, Faculty of Medicine, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada.
A. Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I. Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from Canadian Institutes of Health Research Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose.
Address correspondence to Dr. B.M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, ON M5G 1X8, Canada. Email: brian.feldman@sickkids.ca.
Accepted for publication July 13, 2020.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein, Brian M. Feldman
The Journal of Rheumatology Aug 2020, jrheum.191375; DOI: 10.3899/jrheum.191375
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein, Brian M. Feldman
The Journal of Rheumatology Aug 2020, jrheum.191375; DOI: 10.3899/jrheum.191375